Search results
Zombies: Ranks of world's most debt-hobbled companies are soaring, and not all will survive
Associated Press· 1 day agoThey are called zombies, companies so laden with debt that they are just stumbling by on the brink...
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 23 hours agoPfizer also recently said its new drug, Adcetris, improved overall survival, progression-free ...
Zombies: Ranks of world's most debt-hobbled companies are soaring, and not all will survive
San Francisco Chronicle· 18 hours agoThey are called zombies, companies so laden with debt that they are just stumbling by on the brink...
Zombies: Ranks of world's most debt-hobbled companies are soaring, and not all will survive
Stamford Advocate· 19 hours agoThey are called zombies, companies so laden with debt that they are just stumbling by on the brink...
Zombies: Ranks of world's most debt-hobbled companies are soaring - and not all will survive
Newsday· 1 day agoThey are called zombies, companies so laden with debt that they are just stumbling by on the brink of survival, barely able to pay even the interest on their loans and often ...
RNT Health Insights’ gastric cancer detection tool receives FDA BDD
Medical Device Network via Yahoo Finance· 5 days agoIndia-based clinical-stage medical diagnostics company RNT Health Insights has received breakthrough...
Gena McCarthy’s UNConventional Entertainment Signs With Buchwald
Deadline via Yahoo News· 5 days agoEXCLUSIVE: Gena McCarthy and her UNConventional Entertainment banner has new representation. The ...
Experimental mRNA vaccines gain steam with promising cancer trial results
Semafor via Yahoo News· 5 days agoThe vaccines use messenger RNA — essential molecules that help convert...boost for mRNA vaccines,...
Zombies: Ranks of world's most debt-hobbled companies are soaring - and not all will survive
Albany Times Union· 1 day agoThey are called zombies, companies so laden with debt that they are just stumbling by on the brink...
Bristol Myers Squibb’s Breyanzi shows promise in B-cell malignancy clinical trials
Clinical Trials Arena via Yahoo Finance· 4 days agoWith a median follow-up of 33.9 months, improvements were seen in event-free survival (EFS),...